Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1247

—

2f97527b-8fdc-53e4-9ba8-1d42619407a6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.417
  • DNA_REPAIR+0.352
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.268
  • P53_PATHWAY+0.230
  • PI3K_AKT_MTOR_SIGNALING+0.213
  • OXIDATIVE_PHOSPHORYLATION+0.197
  • UV_RESPONSE_UP+0.197
  • MYC_TARGETS_V1+0.190
  • ADIPOGENESIS+0.180
  • ALLOGRAFT_REJECTION+0.176

Top 10 suppressed

  • PROTEIN_SECRETION-0.376
  • ANGIOGENESIS-0.275
  • UV_RESPONSE_DN-0.263
  • TNFA_SIGNALING_VIA_NFKB-0.256
  • E2F_TARGETS-0.239
  • G2M_CHECKPOINT-0.221
  • KRAS_SIGNALING_UP-0.218
  • MTORC1_SIGNALING-0.188
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.153
  • ESTROGEN_RESPONSE_LATE-0.130

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1097
mng-umap@100
——0.734
2TCGA-94-8491-01A-11R-2326-07
lung-landscapes@6
—cohortSQ10.690
3MNG524
mng-umap@100
——0.676
4MNG571
mng-umap@100
——0.645
5TCGA-LL-A7SZ-01A-32R-A352-07
breast-umap@18
—B0.632
6f844415e-ca2a-4837-b050-06775fdb2ed5
colon-landscapes@1
——0.631
7TCGA-TN-A7HL-01A-11R-A34R-07
head-neck@1
——0.630
8SRR1087031
brain-umap@2
GTEX—0.629
9MV411_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.628
10d22c9285-50cf-4724-9f81-606fb54c00fc
colon-landscapes@1
——0.611

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.417Idelalisib— uncovered
DNA_REPAIR0.352Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.268Inavolisib— uncovered
P53_PATHWAY0.230Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.213Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.197Remibrutinib— uncovered
UV_RESPONSE_UP0.197Idelalisib— uncovered
MYC_TARGETS_V10.190Inavolisib— uncovered
ADIPOGENESIS0.180Inavolisib— uncovered
ALLOGRAFT_REJECTION0.176Idelalisib— uncovered
FATTY_ACID_METABOLISM0.155Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.130Inavolisib— uncovered
COAGULATION0.112Binimetinib— uncovered
XENOBIOTIC_METABOLISM0.111Inavolisib— uncovered
APOPTOSIS0.107Idelalisib— uncovered
PANCREAS_BETA_CELLS0.075Cobimetinib— uncovered
MYOGENESIS0.069Inavolisib— uncovered
APICAL_JUNCTION0.059Inavolisib— uncovered
PEROXISOME0.034Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.031Inavolisib— uncovered